ERBB2 and breast cancer: Furthermore, patients with HER2-low breast cancers were more likely to be diagnosed in the early 2010s (p < 0.001), received more hormonal treatment (15,812/20,636 (76.6%) vs. 6857/10,293 (66.6%), p < 0.001), but less chemotherapy (11,889/20,636 (57.6%) vs. 6539/10,293 (63.5%), p < 0.001) (Table 1).